Despite significant improvements in the prognosis of MM through the use of proteasome inhibitors, immunomodulators, and CD38 monoclonal antibody, the disease remains incurable and requires ongoing treatment [2, 3]. Here, CD38 is linked to Miyoshi myopathy.